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Cytokine regulation of schistosome-induced granuloma and fibrosis.
Schistosomiasis mansoni, a major cause of hepatic fibrosis in many
developing countries, triggers a granulomatous inflammatory reaction in
response to its eggs that lodge in the liver. The egg antigens are eliminated
slowly, and the persistent granulomatous response leads to prolonged
matrix synthesis and hepatic fibrosis. In mice, soluble egg antigens (SEA)
induce interleukin 4 synthesis, promoting a dominant T helper type 2
lymphocyte accumulation with the release of additional cytokines (IL-5,
IL-b), which not only suppress Thi lymphocyte subset cytokines, but
mediate the characteristic pathophysiology. Manipulation of the cytokine
profile with antagonists or exogenous cytokine delivery alters the course of
the hepatic inflammation and fibrosis. In the evolution of the granuloma-
tous response to the S. mansoni eggs, transforming growth factor 13
(TGF-f3) is also produced that may modulate inflammation and regulate
fibrogenesis. In TGF-f31-gene targeted mutant mice that over-express
TGF-f31 (TGF-131 transgenics) or in which TGF-/31 has been inactivated
(TGF-/31—/—; null mutation) or partially inactivated (TGF-f31+/—; null
mutation heterozygotes), the altered production of TGF-f31 impacts on S.
mansoni granuloma and hepatic fibrosis. In addition to the Thl/Th2
cytokine balance, modulation of TGF-f31 may change the outcome of
chronic inflammatory fibrotic disease.
Hepatic fibrosis is a common outcome of chronic liver injury
from persistent viral and helminthic infections, iron overload,
alcoholic liver disease, and a multitude of other causative agents.
Characterized by an increase in extracellular matrix deposition,
including types I and III collagens, proteoglycans, fibronectin and
hyaluronic acid, a cirrhotic liver may contain several-fold more
matrix than normal liver resulting in compromised hepatic func-
tion [1]. Many of the cellular mechanisms leading to hepatic
fibrosis appear to be shared, irrespective of the initiating cause,
and consequently, these events in the liver serve as a paradigm for
understanding fibrotic pathways in other tissues and for the
development of therapeutic interventions.
Infection of the host with the helminth parasite Schistosoma
mansoni results in deposition of parasite eggs in the portal venous
system and entrapment in the perisinusoidal spaces of the liver.
The disseminated eggs induce a granulomatous response where
they lodge, which is responsible for the major pathologic mani-
festations of the disease in over 200 million people infected with
this parasite worldwide [2, 3]. The tissue localization of the
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antigen-secreting eggs initiates a persistent insult to which the
host responds by marshalling leukocyte recruitment and activation
of an inflammatory response. As the host slowly eliminates the
offending antigen, the response persists, evolving into a chronic
granulomatous response. Schistosome-induced periportal fibrosis
is a common sequela of this sustained hepatic inflammation and is
considered to be regulated by products of the inflammatory cell
constituents of the granuloma stimulated by soluble egg antigens
(SEA) [4—6].
Mice are permissive hosts for S. mansoni and provide an
important model for defining the immunopathogenesis of the
disease and, furthermore, a system for assessing the impact of
modulating the host immune response. Although considerable
progress in dissecting the cytokine-mediated pathways leading to
fibrosis has occurred in the past decade, only recently has it been
possible to manipulate the evolving granulomatous response
through cytokine-based interventions [7]. Cytokines control the
host response to the S. mansoni ova from the very outset through
its resolution (Fig. 1). Following the lodging of the ova in the liver,
inflammatory cells begin to exit the circulation and accumulate at
the site, attracted by chemotactic stimuli. The schistosome egg
itself may release chemotactic signals that recruit leukocytes [8]
and in addition, cytokines with potent chemotactic activity, the
chemokines (MCP-1, MIP1a) are released by cells at the site of
tissue injury [9, 10]. Up-regulated adhesion molecules promote
interaction of leukocytes with the endothelium in the liver [11,
12], and with the accumulation of multiple cell types, a complex
array of additional cytokines and other mediators are released,
which in turn influence the continued recruitment of leukocytes
and their phenotypic and functional behavior as the granuloma
evolve.
Granuloma evolution involves a cell-mediated type of immune
response dependent on CD4 T lymphocytes [7]. Antigen-specific
helper T cells exist as functionally polarized T helper (Th) 1 and
Th2 subsets that differentiate from a common precursor, the ThO
cells [13]. Recent evidence indicates that it is the ThO, and then
Th2, subsets of SEA-specific CD4 lymphocytes and their prod-
ucts that dominate the cascade of events leading to granuloma-
tous inflammation by mediating chemotaxis, adhesion, activation
and survival of inflammatory cells within the liver [7]. SEA
triggers a transient increase in IFN7, likely generated by ThU and
NK cells, which is followed by secretion of the Th2 products, IL-4,
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Fig. 1. Cytokine dependent evolution of S.
mansoni granuloma and fibrosis. Entrapment of
S. mansoni eggs in liver and the release of
soluble egg entigens (SEA) trigger an immune
response characterized by a Th2 helper
lymphocyte cytokine profile. Early engagement
of CD4 cells with the release of IL-4 selects
for Th2 lymphocytes and their activation. The
accumulation of eosinophilic and other
leukocytes contributes to active acute
granuloma formation and fibrogenesis as the
SEA is slowly eliminated. Downmodulation of
the immune response results in eventual
involution of the granulomatous response and
residual fibrotic matrix.
IL-5, IL-b and IL-13 (Fig. 1) [14, 15]. This dominant Th2
response, concomitant with down-regulation of the Thi cytokine
network is somewhat unique to these extracellular parasites, since
most intracellular pathogens trigger a Thi lymphocyte profile
(Fig. 2). Convincingly, Th2 clones from liver granulomas indepen-
dently induce formation of circumoval eosinophil-enriched gran-
uloma [16]. Eosinophilia and the production of IgE typify infec-
tion by parasitic worms and contribute to the control of these
parasites, which are too large to be phagocytized. Exogenously
delivered IL-4, critical to the selection of Th2 lymphocytes,
augments these activities, whereas neutralizing antibodies to this
cytokine suppress liver granulomas and IgE levels, and adminis-
tration of anti-IL-S inhibits eosinophilia (Table 1) [17—23]. Similar
consequences have been observed for IL-2 and TNFa, which
exacerbate granuloma formation [18, 22, 24—26], in contrast to
IFNY and IL-12, which favor a Thi response and are both
suppressive (Table 1) [18, 23, 27, 28]. Specific inhibition of
cytokine activity with antibodies (Table 1) [29] or through gene
deletion in knockout mice may profoundly influence granuloma
formation, or may have minimal impact, documenting a causal
relationship for some cytokines, but apparent redundancies for
others.
Approximately six to eight weeks after infection, the balance
shifts from inflammation-promoting to -suppressing cytokines and
fibrosis commences. Thereafter, the active acute granulomatous
response gradually becomes downmodulated into the chronic
phase (12 to 18 weeks). The mechanisms of down-modulation
are poorly understood, but CD8 T cells, macrophages, anti-
idiotype antibodies, and possibly IL-b, have all been implicated
in this process [30—34]. Moreover, chemotherapy can effect a
parasitological cure, with reversal of the granulomatous response,
although reinfection is likely in endemic countries [35].
As inflammation wanes, continued attempts to wall off and
repair hepatic injury lead to development of fibrosis, responsible
for considerable morbidity and mortality in susceptible individu-
als. This reaction to insulate the liver cells from SEA is meant to
benefit the host, but becomes a major source of pathology.
Depending on circumstances, fibrosis may not be reversible [1].
Matrix generation is associated with obstruction of portal blood
flow, portal hypertension and bleeding esophageal varices [36].
Thus, the pathophysiology associated with hepatic fibrosis contin-
ues to warrant elucidation, since its reduction is central to the
control of the overt manifestations of this disease. This aspect of
the host response is likely also mediated by cytokines, although
different cytokines and a shift in the balance of others may
contribute to the deposition of matrix molecules and fibro-
obstructive pathology. Macrophage fibrogenic factors stimulate
matrix production and although the Th2 cytokines have long been
considered to function primarily in the evolution of the granulo-
matous response to S. mansoni egg antigens, emerging evidence
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Fig. 2. Polarization of cytokine response to
infectious pathogens. Whereas many intracellular
pathogens (virus, bacteria, parasites), which
initially encounter non-T, non-B lymphocyte
populations, engender a Thi helper lymphocyte
response, extracellular pathogens such as S.
mansoni activate a dominant Th2 population
and its characteristic profile of cytokines.
Table 1. Effect of cytokine modulation on schistosome-induced granuloma formation and fibrosis
Endogenous
Effect on granuloma formation
Exogenously delivered Neutralization (antibodies)
Livera Livera Lungh Livera Liver Lunga
Cytokine source gran. fibrosis gran. gran. fibrosis gran. References
IFNy NK .1. e t [18, 23, 27]
IL-12 Macrophages e 1 1' [281
IL-4 Th2 [17—22]
IL-2 ThO/Thi ' 1' . . [18, 22, 24, 251
IL-b Th2 [7, 17, 221
Macrophages
B cells
Mast cells
TNF Macrophages [26]
IL-S Th2 e [23]
TGF-/3 Most cells ® e [29]
Natural infection, laid eggs
h Injected (iv.) eggs
puts them right in the middle of the fibrotic response as well. A
number of cytokine intervention tactics have been shown to
preferentially modulate fibrotic outcomes, rather than targeting
the granuloma response as anticipated (Table 1). For example,
treatment of infected mice with anti-IL-4 clearly decreases egg-
induced hepatic fibrosis, yet does not consistently reduce the size
of circumoval granulomas [20]. Moreover, hepatic fibrosis is
diminished when mice are sensitized with S. mansoni eggs to-
gether with IL-12 [28]. By converting the SEA-triggered Th2
response into a Thi dominated cytokine response, IL-12 effec-
tively minimizes fibrosis and host pathology. In these IL-12 studies
[281, reductions in collagen synthesis were not associated with
Determining factor:
IL-4 / IL-12 ratio
Th2
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corresponding changes in TGF-13, considered one of the key
fibrogenic peptides, nor have antibodies to TGF-f3 been shown to
suppress schistosome-induced periportal fibrosis [29].
Nevertheless, several lines of evidence suggest that local pro-
duction of TGF-/3 contributes to schistosome-induced liver dis-
ease, particularly to the accumulation of the extracellular matrix
proteins. TGF-J3 mRNA and protein have been identified within
the lesion, spatially and temporally concordant with deposition of
collagen and other matrix constituents [27—29, 37], and TGF-f3 is
a well-known trigger for the synthesis of these molecules [38—41].
TGF-f3 has been implicated in the pathogenesis of other tissue
fibroses, including progressive renal disease [38], bacterial cell
wall-induced liver fibrosis [42, 43] and in pulmonary fibrosis [44].
Hepatic production of TGF-13 either by intrinsic liver cells and/or
by infiltrating inflammatory cells likely also regulates schistosome-
induced liver fibrosis. Beyond local tissue expression, accumulat-
ing evidence also implicates an involvement of circulating TGF-/3
levels. Blood plasma contains both latent and active TGF-f31 that
is variably increased in disease states [40, 45—47] and which may
participate in tissue fibrotic sequelae [44]. To discern a protective
or confounding role for TGF-f3 in the schistosome fibropathogen-
esis, the fibrotic consequences of chronic granuloma were evalu-
ated in TGF-/3 gene targeted mouse models. Matrix production
and fibrosis in response to natural infection with S. mansoni
worms exhibited distinct profiles in these mice.
Schistosomiasis was induced in gene-targeted mice in which the
TGF-131 gene was either functionally deleted [48, 49] or overex-
pressed [50]. Mice transgenic for an active form of TGF-pl under
the control of murine albumin promoter and enhancer DNA
sequences express the transgene exclusively in the liver and have
elevated plasma levels of TGF-131 [50, 51]. By comparison, the
TGF-131 null mutation (knockout) mice, in which the TGF-pl
gene has been inactivated by homologous recombination, lack the
capability of generating TGF-pl de novo. Plasma TGF-pl levels
in normal mice are routinely less than 10 ng/ml, whereas the
transgenics (line 25) may transiently express  eightfold increases
(at 3 weeks, declining by 6) in circulating TGF-131 [51]. Homozy-
gous TGF-131 null mice (TGF-pl—/—) have no detectable circu-
lating TGF-/31, and the heterozygous mice (TGF-131+/—) have
approximately half as much plasma TGF-pl as normal mice. Since
circulating TGF-131 becomes widely distributed in tissues [52],
tissue concentrations likely reflect gene expression, even if its
source is tissue specific, as in the overexpressing transgenics [51].
Interestingly, whether mice lack TGF-131 or overexpress this
peptide, they appear to constitutively develop several overlapping
pathologies [41, 48—50, 52—55] including hepatic inflammation
and myocarditis within three to four weeks. In fetal mice and for
two to four weeks postnatally, however, hepatic histologic features
of all mice were indistinguishable [49, 50].
Newborn or five- to eight-week-old animals were infected
percutaneously with S. mansoni cercariae shed from snail vectors,
and the livers examined eight weeks later. Since nearly complete
mortality characteristically occurs in TGF-f31 homozygous null
mice before eight weeks, these studies, of necessity, focused on
TGF-f31 heterozygotes (—50% plasma TGF-/31 levels) and trans-
genics (—8-fold increase in plasma TGF-f31 at 3 weeks). Within
weeks after ectopically deposited eggs were trapped in the pen-
sinusoidal spaces of the liver, inflammatory cell infiltration and
granuloma development occurred in all animals. Furthermore,
granuloma size around individual eggs as measured by volume
and diameter was surprisingly similar in the TGF-f31 heterozy-
gotes and transgenics compared to the wild-type mice. The
cellular composition of the lesions also appeared similar in the
mice expressing different levels of TGF-f31, although increased
necrosis was occasionally observed in the center of the TGF-131
heterozygote (+/—) granuloma (Frazier-Jessen et a!, manuscript
in preparation).
In the TGF-/31 transgenic mice, abundant extracellular matrix
was evident on Masson trichrome stain. Matrix-generating stellate
cells, a pericyte also known as Ito cells that are analogous to
mesangial cells, are likely activated by TGF-f31 and/or other
growth factors to proliferate and enhance their synthetic activity
producing increased mRNA expression for type I and III collagen
in the infected livers and increased liver hydroxyproline (Wahi et
al, manuscript in preparation). Conversely, heterozygous null
mutation mice with less potential TGF-131 (gene dosage effect)
manifest reduced collagen synthesis (60% decrease in hy-
droxyproline) compared to wild-type mice (TGF-/3+/+) at eight
weeks, during the initial matrix synthetic phase.
Because the TGF-f31 null mice do not typically survive beyond
three to four weeks, it is not possible to monitor the impact of
TGF-f31 deficiency on S. mansoni-induced hepatic granuloma
evolution and fibrosis in the course of natural infection, which
requires 8 to 12 weeks. As an alternative to natural infection with
larvae, we injected schistosome eggs (5 x i0) intravenously. In
this model, eggs lodge in the pulmonary veins, where they produce
a condensed and synchronous host response in the lungs, the
immunopathology of which can be assessed within 2 to 4 weeks.
Using this system, TGF-/31+/+, TGF-pl—/—, TGF-131+/—, and
TGF-f31 transgenic animals were injected with eggs and two weeks
later, lung tissues were analyzed for egg deposition and its
attendant pathology. Within the lung, there is generally less
fibrosis, but increased arteritis compared with the response to
eggs in the liver. The pulmonary granuloma are also characterized
by a Th2 cell and cytokine response to SEA and airway epithelial
cytokine secretion may also amplify inflammatory cascades in
response to SEA. In this regard, IL-4 has been shown to up-
regulate intracellular adhesion molecule expression (ICAM) on
bronchial epithelial cells to promote leukocyte recruitment and
retention within the airway epithelium [56] and to increase
15-lipoxygenase activity [57]. Moreover, TGF-p modulates a
multiplicity of airway epithelial cell functions including prolifera-
tion, fibronectin production, integrins, proto-oncogene expression
and also the expression of urokinase and plasminogen activator
inhibitor [58—62]. Induction of pulmonary granuloma in the
absence of TGF-/31 (TGF-pl—/—) is associated with reduced
numbers, but larger pulmonary lesions than in the normal host
(Frazier-Jessen et al, manuscript in preparation). On the other
hand, the TGF-131 null mutation heterozygotes, with reduced, but
not absent TGF-131, had an intermediate number of granuloma
around single eggs compared to their normal littermates. The
mechanism whereby reduced TGF-pl levels inhibit granuloma
initiation is unclear, but may reflect the absence of the many
proinflammatory activities of TGF-pl, including initiation of
chemotaxis and early cytokine synthesis [39—41]. The increased
size of the granuloma, once established in mice depleted of
TGF-J31, may reflect the lack of immunosuppressive potential of
TGF-pl on activated immune cells [39—41]. Consistent with this
hypothesis, mice with excess TGF-f31 (transgenics) tended to have
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smaller pulmonary granuloma (Frazier-Jessen et al, manuscript in
preparation).
These data document the participatory role of TGF-f31 in
granuloma development and also in hepatic fibrosis in response to
S. mansoni infection. Although fibrotic manifestations appear
dependent on TGF-/31 levels, fibrosis is not eliminated in the
absence of TGF-/31, nor is it overwhelming in mice overexpressing
this fibrogenic peptide. These observations emphasize the multi.
factorial nature of the signals involved in the complex pathophys-
iology of this and other fibrotic diseases. Nonetheless, as a link in
the cytokine cascade, TGF-/31 represents a potential target for
novel therapies in fibrotic disorders.
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